Mercia Fund Management has been in the spotlight in the UK press recently with articles in the Financial Times and The Sunday Times. In an article in The Sunday Times on 30 September 2012, “Spotlight on tax saving schemes”, Mercia Fund Management’s Growth Fund was highlighted as a good example for tax efficient saving. “Mercia
Investors gain update on Venture Capital Trusts, Enterprise Investment Schemes and hybrid EIS/SEIS funds Birmingham, 6 November 2012. Mercia Fund Management (MFM) will be presenting its Mercia Growth Fund, a ‘hybrid’ fund offering combining separate Seed EIS (SEIS) and later stage EIS investments, at the VCT and EIS Investor Forum on 21 November 2012. Attended
FOR IMMEDIATE RELEASE‘OCTAVE’ Study Will AssessColoAd1in Patients with Ovarian Cancer OXFORD, UK – 31 October 2012– PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1
North Brunswick, NJ and London, UK – 23 October 2012. Biotecnol, Inc. and PolyTherics Ltd. have entered into a collaboration for the development of multi-specific Tribody Drug Conjugates (TDCs). The companies will combine Biotecnol’s Tribody technology with PolyTherics’ proprietary site-specific linker technologies to attach cytotoxic payloads to various Tribodies for targeted cancer therapy. Tribody molecules
Ideas of the future get a chance to blossom with multi million pound investment fund Bright ideas emerging from universities in the West Midlands now have the chance to become reality with the continued support of the vital Mercia Fund 1. Over the next 3 years, innovative technology ideas that have been developing quietly through
London, UK, 15 th October 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to enable the development of better biopharmaceuticals, has extended its collaboration with a top five pharmaceutical company to further investigate applications of PolyTherics’ polymer, PolyPEG®. PolyPEG™ is a patented polymer designed to extend the half-life in the body of therapeutic proteins
Mark Payton, managing director of Mercia Fund Management, talks university spin- outs and looks at successful companies from the University of Warwick.Working with eight Midlands’ universities, Mercia Fund Management has supported spin- outs from seed to successful exit through investment, sourcing the right people to manage the funded company, and providing strategic input. This article
‘Evolve’ Study Will Assess Safety and Tolerability of Unique Anti-Cancer Agent, ColoAd1 OXFORD, UK – 26 September 2012 – PsiOxus Therapeutics, Ltd. (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial
LONDON – 13 September 2012 – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the conversion of almost £1 million ($1.5 million) of loan notes from the Wellcome Trust, a leading global charitable foundation. The loan conversion follows a Series B round of equity financing totaling £22 million ($34 million) closed in July 2012. The loan notes
OBN 2012 Annual Awards recognise PsiOxus for £22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine. Mercia Fund Management MD Mark Payton attended the OBN 2012 Annual Awards Dinner last night and is delighted to announce that PsiOxus Therapeutics, Ltd. (PsiOxus) won the Best Biotech Fund Raiser award. PsiOxus